Scientific Areas of Expertise: Drug Discovery and Development, Molecularly Targeted Therapeutics, Precision Medicine
For unparalleled contributions to establishing personalized, anticancer therapeutics including his co-development of imatinib, the first tyrosine kinase inhibitor effective for the treatment of chronic myelogenous leukemia and beneficial when administered to patients with gastrointestinal stromal tumors or small cell lung cancer, research which has since provided the foundation for the development of numerous molecular targeted therapeutics.
A pioneering architect of precision oncology, Dr. Matter transformed targeted cancer therapy by championing the proposition that selective inhibition of a dominant oncogenic kinase could produce profound and durable clinical responses. He built and led the teams that discovered and advanced imatinib, translating ATP-competitive inhibition of BCR-ABL from a high-risk research concept into clinical development. Landmark trials subsequently showed that imatinib produced rapid hematologic and cytogenetic responses in chronic myeloid leukemia (CML), with later studies documenting durable molecular remissions and markedly improved long-term survival. This work provided compelling proof that a rationally designed small molecule could suppress a genetically defined cancer driver without the nonspecific toxicity of conventional chemotherapy. Imatinib’s activity in advanced gastrointestinal stromal tumors, driven predominantly by mutant KIT and in selected cases by imatinib-sensitive PDGFRA alterations, extended this therapeutic principle to solid tumors.
Building on this success, Dr. Matter championed the development of next-generation tyrosine-kinase inhibitors, notably nilotinib, which was rationally designed for greater potency against BCR-ABL and activity against many imatinib-resistant kinase-domain mutations. Structural analyses showed that imatinib recognizes and stabilizes an inactive ABL conformation, which established conformational selectivity as a central principle of kinase inhibitor design. These iterative advances codified a precision-oncology playbook centered on defining an oncogenic driver, optimizing inhibitor–target interactions, anticipating resistance, and engineering successive therapeutic solutions. Clinically, this work transformed CML from a frequently fatal leukemia into a chronic, manageable disease for many patients and supplied a model that now informs targeted drug development across cancer. Through scientific leadership that connected discovery chemistry, mechanistic biology, clinical translation, and resistance-informed development, Dr. Matter helped establish the modern paradigm of mechanism-based precision medicine.
Selected Awards and Honors
2013 Szent-Györgyi Prize, National Foundation for Cancer Research, Rockville, Maryland
2004 Life-time Achievement Award, The Third Annual Pharmaceutical Achievement Awards, IBC Life Sciences, Westborough, Massachusetts
2002 AACR-Bruce F. Cain Memorial Award, American Association of Cancer Research, Philadelphia, Pennsylvania
2002 Novartis Excellence Award for Innovation, Novartis, Basel, Switzerland
2001 Warren-Alpert Prize, Warren Alpert Foundation in partnership with Harvard Medical School, Providence, Rhode Island
[Institutional affiliations listed for Fellows reflect those held at the time of their induction into the AACR Academy.]